Inhibikase Therapeutics, Inc. · NASDAQ:IKT
ADAR1 Capital Management, LLC reported a 9.99% stake in Inhibikase Therapeutics, Inc. (Schedule 13G)
Event Dec 31, 2024 · Filed Feb 14, 2025
ADAR1 Capital Management, LLC reported a 9.99% stake in Inhibikase Therapeutics, Inc., 6,809,355 shares, as a passive investor on Dec 31, 2024. Filed Feb 14, 2025 (Schedule 13G).
- Stake
- 9.99%
- Shares
- 6,809,355
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 3 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| ADAR1 Capital Management, LLC | 9.99% | 6,809,355 |
| ADAR1 Capital Management GP, LLC | 9.99% | 6,994,246 |
| Daniel Schneeberger | 9.99% | 6,809,355 |
Source
Related
- Inhibikase Therapeutics, Inc.
- ADAR1 Capital Management, LLC
- Inhibikase Therapeutics, Inc. shareholders
- Schedule 13G/A · ADAR1 Capital Management, LLC · May 15, 2026
- Schedule 13G/A · ADAR1 Capital Management, LLC · Feb 17, 2026
- Schedule 13G/A · ADAR1 Capital Management, LLC · Aug 14, 2025
- Schedule 13G/A · Perceptive Advisors LLC · Aug 14, 2026
- Schedule 13G/A · Nantahala Capital Management, LLC · Aug 14, 2026
- Schedule 13G/A · Sands Capital Life Sciences Pulse Fund II, L.P. · Aug 13, 2026
- Form 4 · Berman Dennis N · Jul 31, 2026
- Form 4 · RA Capital Healthcare Fund LP · Jul 31, 2026